A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer

A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer

Background and objective Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In...

Full description

Bibliographic Details
Main Authors: Mingzhi LI, Liyan XU, Lili GUO, Wei WU, Zan LIU, Heling SHI, Qiyi MENG, Zhe LIU, Xinyong ZHANG, Yunzhong ZHU, Junfang TANG, Hong TAO, Yuhua WU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-12-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Erlotinib
Treatment outcome
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.18&path[]=1242

Internet

http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.18&path[]=1242

Similar Items